109 related articles for article (PubMed ID: 25477122)
21. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines as novel antitumor agents.
Tsuzuki Y; Tomita K; Sato Y; Kashimoto S; Chiba K
Bioorg Med Chem Lett; 2004 Jun; 14(12):3189-93. PubMed ID: 15149673
[TBL] [Abstract][Full Text] [Related]
23. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
24. Idelalisib approved for trio of blood cancers.
Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
[No Abstract] [Full Text] [Related]
25. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
26. Destroying malignant white cells.
Baum MS
J N J Dent Assoc; 2008; 79(1):18-9. PubMed ID: 18557488
[No Abstract] [Full Text] [Related]
27. [Oral molecular targeting agents in hematological malignancy].
Wakabayashi S; Ohashi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1214-8. PubMed ID: 20647701
[TBL] [Abstract][Full Text] [Related]
28. [Chemotherapy in elderly patients with hematological malignancies].
Ohnishi K
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
[TBL] [Abstract][Full Text] [Related]
29. Targeting RNA polymerase I transcription and the nucleolus for cancer therapy.
Hannan RD; Drygin D; Pearson RB
Expert Opin Ther Targets; 2013 Aug; 17(8):873-8. PubMed ID: 23862680
[TBL] [Abstract][Full Text] [Related]
30. Blood cancers, chemotherapy and the risks of neutropenia.
Butters G
Nurs Times; 2011 Mar 22-28; 107(11):19. PubMed ID: 21682165
[No Abstract] [Full Text] [Related]
31. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
32. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
33. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
34. Oncology Conference Highlights, Q4.
Leavitt J; DeVito T; Saleh N
Oncology (Williston Park); 2019 Jan; 33(1):8-10. PubMed ID: 30731012
[No Abstract] [Full Text] [Related]
35. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
36. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
Hilton J; Gelmon K; Bedard PL; Tu D; Xu H; Tinker AV; Goodwin R; Laurie SA; Jonker D; Hansen AR; Veitch ZW; Renouf DJ; Hagerman L; Lui H; Chen B; Kellar D; Li I; Lee SE; Kono T; Cheng BYC; Yap D; Lai D; Beatty S; Soong J; Pritchard KI; Soria-Bretones I; Chen E; Feilotter H; Rushton M; Seymour L; Aparicio S; Cescon DW
Nat Commun; 2022 Jun; 13(1):3607. PubMed ID: 35750695
[TBL] [Abstract][Full Text] [Related]
37. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
38. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
39. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly.
Ohta M
Geriatr Gerontol Int; 2009 Jun; 9(2):115-23. PubMed ID: 19740353
[TBL] [Abstract][Full Text] [Related]
40. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.
Fulda S
Leukemia; 2012 Jun; 26(6):1155-65. PubMed ID: 22230799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
